December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Topical Ocular Delivery of Nepafenac Inhibits Preretinal Neovascularization
Author Affiliations & Notes
  • DP Bingaman
    Pharmaceutical Products Research Alcon Research Ltd Fort Worth TX
  • K Holt
    Pharmaceutical Products Research Alcon Research Ltd Fort Worth TX
  • MA Kapin
    Pharmaceutical Products Research Alcon Research Ltd Fort Worth TX
  • Footnotes
    Commercial Relationships    D.P. Bingaman, Alcon Research Ltd. E; K. Holt, Alcon Research Ltd. E; M.A. Kapin, Alcon Research Ltd. E.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3920. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      DP Bingaman, K Holt, MA Kapin; Topical Ocular Delivery of Nepafenac Inhibits Preretinal Neovascularization . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3920.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose:COX II activation has been implicated in ishcemia-related VEGF upregulation and pathologic angiogenesis. Nepafenac, a topically delivered NSAID, has excellent corneal penetration. We investigated the utility of nepafenac against posterior segment neovascularization following topical ocular delivery in a rat OIR model. Methods:Preretinal neovascularization (NV) was produced in a rat model of oxygen-induced retinopathy (OIR) by modulating inspired oxygen levels between 50% & 10% from P0-P14 in neonatal rat pups, where 50% was maintained for 48 hours from P11-12. From P14-20, 4 litters of rat pups were removed into room air and each litter was randomized into 3 topical QID OU dosing groups, including vehicle (n=18 pups), 0.1% nepafenac (n=23 pups), and 0.5% nepafenac (n=22 pups). At P20, all rats were euthanized and retinas were harvested, ADPase-stained, and prepared as flat mounts. Computerized image analysis was used to determine the median clockhours of preretinal NV per pup in each treatment group. Treatment group medians were compared via nonparametric analyses, where P<0.05 was considered significant. Results:Topical ocular delivery of 0.1% nepafenac QID OU significantly inhibited preretinal NV by 55% in this rat OIR model as compared to vehicle (P=0.02). Topical ocular delivery of 0.5% nepafenac appeared to decrease preretinal NV ≷30%, however, the difference was not significant. The preretinal NV scores per treatment group were as follows: vehicle = 3.75, 0.1% nepafenac = 1.7, and 0.5% nepafenac = 2.5. Conclusion:Nepafenac, a novel nonsteroidal antiinflammatory prodrug that has rapid corneal penetration, is able to inhibit ischemia-related preretinal NV following topical ocular dosing. The level of antiangiogenic activity provided by topical nepafenac is equivalent to a variety of agents tested in rodent OIR models through intravitreal and systemic routes of administration.

Keywords: 514 pharmacology • 483 neovascularization • 554 retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.